Caribou Biosciences Inc
Company Profile
Business description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Contact
2929 7th Street
Suite 105
BerkeleyCA94710
USAT: +1 510 982-6030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
147
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,573.40 | 48.60 | 0.57% |
| CAC 40 | 7,936.82 | 53.19 | 0.67% |
| DAX 40 | 24,039.96 | 104.98 | 0.44% |
| Dow JONES (US) | 42,792.07 | 137.33 | 0.32% |
| FTSE 100 | 8,757.34 | 58.03 | 0.67% |
| HKSE | 23,681.48 | 348.76 | 1.49% |
| NASDAQ | 19,215.46 | 4.36 | 0.02% |
| Nikkei 225 | 37,529.49 | 30.86 | 0.08% |
| NZX 50 Index | 12,644.23 | 15.16 | 0.12% |
| S&P 500 | 5,963.60 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,343.30 | 48.20 | 0.58% |
| SSE Composite Index | 3,380.48 | 12.90 | 0.38% |